Technical Leaders Quarterly Update
Published: June 30, 2026
This content is for informational purposes only. This should not be construed as solicitation. The general public should consult their financial advisor for additional information related to investment decisions.
Momentum strategies showed a strong start to the year in comparison to broader benchmarks.

Momentum strategies had a productive first half of the year in comparison to broader benchmarks. This was particularly evident for large cap equities, where the Invesco Dorsey Wright Momentum ETF (PDP) tripled the return of the Russell 1000 ETF benchmark (IWB) for the first half (12/31/25-6/30/26). Small cap momentum was also strong, as the Invesco Dorsey Wright SmallCap Momentum ETF (DWAS)outpaced the large-mid counterpart, although it posted outperformance of a smaller magnitude against the Russell 2000 ETF benchmark (IWM).

The performance table below compares the price return of the Invesco Dorsey Wright Momentum ETF (PDP) and the Invesco Dorsey Wright SmallCap Momentum ETF (DWAS) to their respective benchmarks through the first half, while the two bottom tables zoom out to broader, calendar year performance from 2001 to 2026 (through 6/30/2026).

Our approach toward momentum through relative strength analysis looks to capitalize on consistent trends across the market. Changing trends cause the portfolios to readjust to maintain exposure to the strongest areas. Underperformance is typical during those environments as areas that had demonstrated relative strength fall in our rankings. The most important step in our approach comes next – those areas that have declined in strength are sold to make room for the new leaders. Any investment process is going to produce a portfolio of winners and losers. Relative strength analysis gives us a systematic way to cull the losers and constantly push the portfolio toward the strongest areas of the market.  

In the most recent quarter, we saw 53 changes (out of 100 holdings) in PDP and 123 changes (out of 200 holdings) in DWAS, repositioning both portfolios toward areas of leadership as we enter the second quarter. Both portfolios saw more turnover at this evaluation than either strategy saw last quarter.

Below you'll find an update about the specific changes made in both strategies with the most recent index reconstitution. Keep in mind that removed positions likely no longer maintain characteristics of superior relative strength; meanwhile, additions have improved to a place of leadership and could be ideas to consider.

Invesco Dorsey Wright Momentum ETF (PDP)

The stock-selection process behind the Invesco Dorsey Wright Momentum ETF (PDP) is simple yet robust. Every quarter, we apply the relative strength process to compare approximately 1,000 large- and mid-cap US stocks and select the strongest 100 names. The quarterly reconstitution process's goal is to weed out the weak names and realign the portfolio toward strength. As mentioned before, with this most recent reconstitution and rebalance, we removed 53 stocks and added 53 new stocks, which we've compiled in the tables below. Several observations:

  • Technology saw the most improvement in Q2, accounting for 42% of the new additions.
  • Industrials saw the most removals from the portfolio but also accounted for the second most additions. This highlights rotating strength within the sector.  
  • Healthcare made its way back into the frame, accounting for the third most additions with six names added. This laggard sector has mounted a resurgence in recent weeks.
  • For the third consecutive quarter, consumer cyclical stocks marked one of the largest declines in overall allocation, dropping the second-most names of any sector.

Invesco Dorsey Wright SmallCap Momentum ETF (DWAS)

The stock-selection process used in DWAS is like PDP. Every quarter, we apply the relative strength process to compare approximately 2,000 US-listed small-cap stocks and select the strongest 200 names. With this most recent reconstitution and rebalance we pushed the portfolio towards strength by removing 123 stocks and adding 123 new stocks, which we've outlined in the table below. However, and perhaps unique to DWAS, not all stocks that were removed are technically weak. We have received this question in the past, so we want to address it here.

One reason for these removals is due to stocks exceeding the market cap filter. High-momentum stocks should, ideally, increase in market cap which means that sometimes a name will exceed the small-cap maximum at the end of a quarter. This is not the norm, but worth keeping in mind when reviewing the changes. Several takeaways:

  • Healthcare saw the largest proportion of overall additions over the last quarter at 24% of the new names. This was due to increasing momentum from many of the biotechnology companies included in the inventory.
  • Industrials saw the next largest number of new names added, accounting for 22% of the newcomers.
  • Technology and consumer cyclicals round out the sectors with double-digit counts of additions. These areas, alongside industrials and the biotech-centered healthcare adds, highlight the risk-on positioning within DWAS as we head into the second half of the year.


Disclosures:

This article is intended for Financial Professional Use Only.

Management and other expenses can have a material impact on performance when compounded over time. Past performance, hypothetical or actual, does not guarantee future results. In all securities trading there is a potential for loss as well as profit. It should not be assumed that recommendations made in the future will be profitable or will equal the performance as shown.

Click here for more information from Invesco on the Invesco DWA Momentum ETF (PDP): https://www.invesco.com/us/financial-products/etfs/product-detail?audienceType=Investor&ticker=PDP

Click here for more information from Invesco on the Invesco DWA SmallCap Momentum ETF (DWAS): https://www.invesco.com/us/financial-products/etfs/product-detail?audienceType=Investor&productId=ETF-DWAS

Dorsey, Wright & Associates, LLC is owned by Nasdaq, Inc. and we have affiliates who also provide financial services, research, information, and act as Brokers/Dealers to a wide variety of clients. Our affiliates use the information we create to create indexes, which are then used to create Exchange Traded Funds. These things create a potential conflict of interest in that we may have an incentive to promote or use the products and services of our affiliates and business partners. A number of Dorsey Wright representatives are registered with and hold securities licenses with the affiliate broker-dealers. In this capacity, they assist with the marketing and distribution of Exchange Traded Products.

Back to report

DISCLOSURE

This report is for Internal Use Only and not for distribution to the public. While we make every effort to be free of errors in this report, it contains data obtained from other sources. We believe these sources to be reliable, but we cannot guarantee their accuracy. Investors who use options should read the Options Disclosure Document before making any particular investment decision. Officers or employees of this firm may now or in the future have a position in the stocks mentioned in this report. Dorsey, Wright is a Registered Investment Advisor with the U.S. Securities & Exchange Commission. Copies of Form ADV Part II are available upon request.
Equity prices provided by Thomson-Reuters. Cross Rate prices provided by Tenfore Systems. Option prices provided by OPRA
Copyright © 1995-2026 Dorsey, Wright & Associates, LLC.®
All quotes displayed are delayed 20 minutes
Disclaimer/Terms of Use/Copyright